Cheng Jie, Wu Yangping, Wang Yuxi, Wang Chengdi, Wang Yanyan, Wu Chengyong, Zeng Shaoxue, Yu Yamei, Chen Qiang
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center of Biotherapy, Chengdu 610041, People's Republic of China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center of Biotherapy, Chengdu 610041, People's Republic of China; Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, No. 37, Guo Xue Street, Chengdu, Sichuan 610041, People's Republic of China.
Biochem Biophys Res Commun. 2018 Jan 1;495(1):185-188. doi: 10.1016/j.bbrc.2017.10.104. Epub 2017 Nov 2.
Microtubules are composed of αβ-tubulin heterodimers and have been treated as highly attractive targets for antitumor drugs. A broad range of agents bind to tubulin and interfere with microtubule assembly, including colchicine binding site inhibitors (CBSIs). Tubulin Polymerization Inhibitor I (TPI1), a benzylidene derivative of 9(10H)-anthracenone, is a CBSI that inhibits the assembly of microtubules. However, for a long time, the design and development of anthracenone family drugs have been hindered by the lack of structural information of the tubulin-agent complex. Here we report a 2.3 Å crystal structure of tubulin complexed with TPI1, the first structure of anthracenone family agents. This complex structure reveals the interactions between TPI1 and tubulin, and thus provides insights into the development of new anthracenone derivatives targeting the colchicine binding site.
微管由αβ-微管蛋白异二聚体组成,一直被视为抗肿瘤药物极具吸引力的靶点。多种药物可与微管蛋白结合并干扰微管组装,其中包括秋水仙碱结合位点抑制剂(CBSIs)。微管蛋白聚合抑制剂I(TPI1)是9(10H)-蒽酮的苄叉衍生物,是一种抑制微管组装的CBSI。然而,长期以来,蒽酮类药物的设计与开发因缺乏微管蛋白-药物复合物的结构信息而受阻。在此,我们报道了微管蛋白与TPI1复合物的2.3 Å晶体结构,这是蒽酮类药物的首个结构。该复合物结构揭示了TPI1与微管蛋白之间的相互作用,从而为靶向秋水仙碱结合位点的新型蒽酮衍生物的开发提供了思路。